Louisville, CO, September 8, 2005 - Replidyne, Inc., a privately held biopharmaceutical company focused on the discovery and development of new antiinfective drugs, announced today that it has raised $62.5 million in a Series D financing led by several large institutional investors, including new investors Duquesne Capital Management, Healthcare Investment Partners and MDS Life Sciences Technology II funds (served by MDS Capital Corp.). Also participating in this financing round were existing investors HealthCare Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical Fund, Sequel Venture Partners, Temasek Holdings Pte Ltd and Quintiles Transnational. Aquilo Partners, Inc. served as the exclusive placement agent for Replidyne.

Additionally, the Company announced that Henry Wendt, Founder and Managing Partner of Healthcare Investment Partners and former Chairman and Chief Executive Officer of SmithKline Beckman prior to its merger with Beecham, has joined Replidyne's Board of Directors.

"The strong interest from such high-quality investors validates our confidence in the potential of our lead product candidate, faropenem medoxomil, and the ability of a superb team to drive the product to approval and commercialization," said Kenneth J. Collins, Replidyne's President and Chief Executive Officer. "The proceeds from this offering are expected to carry us through the launch of faropenem for respiratory tract infections and will also allow us to move REP8839, a topical antibiotic being developed to treat infections caused by antibiotic-resistant bacteria such as MRSA, into clinical trials. We are pleased with the enthusiasm of our new investors as well as with the commitment shown to the Company by our existing investors. Additionally, we are excited that Henry Wendt will join our Board of Directors. Henry is one of the most experienced and respected pharmaceutical executives in the country and we will benefit greatly from his broad industry experience."

Replidyne's lead product, faropenem medoxomil, is an orally available antibiotic for treatment of community acquired infections such as respiratory tract infections (RTIs). Replidyne expects to file a New Drug Application (NDA) in multiple indications for faropenem in late 2005 and, if approved by the FDA, to launch the product in late 2006. Faropenem has been tested for safety and efficacy in nine pivotal Phase III clinical trials against RTIs in more than 3,400 patients. If approved, faropenem would be the first oral antibiotic of the penem class to be marketed in the United States. Penems are a subclass of beta-lactams, the most widely prescribed class of antibiotics. Replidyne is also developing the product for additional adult and pediatric indications.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. In addition to preparations for an NDA for faropenem, Replidyne's current development programs include higher dose/shorter course faropenem, additional adult and pediatric indications for faropenem, and topical applications of REP8839. Replidyne also maintains a research team focused on developing additional drug candidates, including a preclinical program directed to inhibitors of bacterial DNA replication. For additional information about Replidyne, please visit: www.replidyne.com.